经卡介苗免疫疗法改善的支气管源性癌患者的生存率。
Survival of patients with bronchogenic carcinoma modified by BCG immunotherapy.
作者信息
Warren S E, Crispen R G, Nika B
出版信息
Am Surg. 1978 Jul;44(7):428-31.
PMID:686527
Abstract
Fifty-five patients with stage II and III bronchogenic carcinoma were randomized into one group of 21 treated conventionally, and another group of 34 additionally vaccinated with BCG. Vaccinated patients survived, on average, 11 weeks longer than controls. A lag of about six months existed before consistent differences became apparent.
摘要
55例II期和III期支气管源性癌患者被随机分为两组，一组21例接受常规治疗，另一组34例额外接种卡介苗。接种疫苗的患者平均比对照组多存活11周。在一致的差异变得明显之前，大约有六个月的延迟期。
Zotero 插件